Pharma Firms Get Big Relief as Government Drops Mandatory Re-labelling Rule After GST Cut
- By Newsdesk
- New Delhi
- Sep 17, 2025
The Indian pharmaceutical industry has been handed a major reprieve following a government decision that waives the requirement to recall and re-label medicines already in the market due to the recent Goods & Services Tax (GST) rate cut.
Instead of forcing manufacturers to physically change labels on stock released before September 22, 2025, the National Pharmaceutical Pricing Authority (NPPA) has instructed companies to update price lists or issue supplementary price lists to dealers, retailers and government regulators. These price updates must reflect the lowered GST rates and the revised Maximum Retail Prices (MRPs) of drugs and medical devices. Retailers, too, will have to display the updated prices.
This move eases logistical burdens and cost pressures on pharma companies, who had voiced concerns about the complexities and expenses involved in recalling, re-labelling or re-sticking medicine packs already on shelves. It also helps ensure that supply chains are not disrupted and that patients won’t face medicine shortages. Compliance will now be enforced at the retailer level.
The clarification comes in the wake of the 56th meeting of India’s GST Council (held September 3, 2025), during which pharmaceutical rates were rationalised. The NPPA’s guidance aims to make the implementation of this rate change smoother, balancing regulatory oversight with practical business needs.